阻断光滑胆固醇化:克服癌症药物耐药性的战略
Steven Y Cheng1, Ying E Zhang2
1State Key Laboratory of Reproductive Medicine, Department of Medical Genetics, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
研究人员确定了Q29,一种新型化合物,通过阻断胆固醇修饰光滑 (SMO) 来抑制刺信号传递. 这一发现为抑制瘤生长和克服对SMO抑制剂的耐药性提供了新的策略.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 药用化学 医学化学
背景情况:
- 刺信号通路对胚胎发育至关重要,并与各种癌症有关.
- 滑化 (SMO) 是刺通路中的一个关键受体,是现有疗法所针对的.
- 对SMO抑制剂的耐药性构成了重大的临床挑战.
研究的目的:
- 为了识别抑制刺信号的新型化合物.
- 调查Q29.9的作用机制.
- 在体外和体内评估Q29的抗瘤疗效.
主要方法:
- 合成Q29,一种合成的二氧化.
- 生物化学测试以评估抑制SMO的胆固醇修饰.
- 基于细胞的测试来测量刺信号活动.
- 使用瘤模型进行体外和体外研究.
主要成果:
- Q29有效地阻断了SMO的共价胆固醇修饰.
- Q29抑制了刺的信号传输.
- Q29抑制瘤细胞在体外和体内生长.
- Q29在克服对现有SMO抑制剂的耐药性方面表现出有效性.
结论:
- Q29是一种具有抗瘤活性的刺信号传递的强有力的抑制剂.
- Q29的机制涉及阻断SMO胆固醇的修饰.
- Q29代表了一种有前途的治疗候选药物,用于治疗由刺信号驱动的癌症,包括耐药病例.
更多相关视频
14:51Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
相关概念视频
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Carrier-Mediated Transport
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Drug Biotransformation: Overview
